Autoimmune type 1 diabetes (T1D) has long been associated with significant health and life-quality impacts, including the need for insulin therapy for life. However, significant changes in our understanding of autoimmune T1D are happening right now. These changes will help to identify people with presymptomatic disease so that they can prepare for life with autoimmune T1D. That’s why Sanofi has developed BR1DGE – an expert-led medical education program designed to keep you up-to-date with the latest developments.
Recent Resources
Exploring the Impact of Diagnosis
The burden associated with a diagnosis of autoimmune T1D can be wide-ranging. This video describes the impact of diagnosis on an individual and their family.
Early Identification of Type 1 Diabetes: Who Might Benefit from Screening for Autoantibodies?
Why and Who: an overview of the key considerations and decisions that inform screening people for islet autoantibodies.
The Silent Stages of Type 1 Diabetes: An Overview
Staging of autoimmune T1D allows us to track the progressive nature of the disease, from autoimmunity through to insulin dependence.
Upcoming Events
A world-renowned faculty at your fingertips
The BR1DGE program features specialists from the field of autoimmune T1D, as well as leading voices from the wider community, including patient advocacy groups and payer representatives. Through close collaboration with the faculty, BR1DGE gives you access to cutting-edge scientific content relevant to your needs.
